Ibandronate Sodium
Brand names: Ibandronate Sodium
At a glance
- Medicare prescriptions, 2024
- 565,430
- Medicare drug cost
- $16.2M
- Average cost per prescription
- $28.71
- Clinicians who prescribed it
- 20,393
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Ibandronate Sodium Tablets are a bisphosphonate indicated for the treatment and prevention of post-menopausal osteoporosis. Limitations of Use The optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use..
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 32.5%
- Internal Medicine 31.5%
- Nurse Practitioners 10.2%
- Physician Assistants 4.7%
- General Practice 4.4%
- Rheumatology 4.3%
- OB-GYN (Obstetrics & Gynecology) 3.9%
- Endocrinology & Diabetes 3.6%
- Hematology & Oncology 1.3%
- Geriatric Medicine 1.1%
- Cardiology 0.3%
- Medical Oncology 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 27% from 2019 to 2024.
Biggest change by state since 2019
- Minnesota +65%
- Florida +55%
- Missouri +49%
- Alabama +49%
- South Carolina +48%
- Puerto Rico (smallest change) −11%
- Massachusetts (smallest change) −1%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Aurobindo Pharma Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 150 mg | white capsule, 14 mm | X 78 |
Bionpharma Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 150 mg | yellow capsule, 14 mm | ID 150 |
Dr. Reddy's Laboratories Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 150 mg | white capsule, 13 mm | R575 |
Golden State Medical Supply, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 150 mg | white oval tablet, 14 mm | APO IBA150 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.